The most authoritative list of entrepreneurial companies in China - the VENTURE50 list of investment-worthy companies, jointly organized by Zero2IPO and Investment Community, announced its preliminary results yesterday.SIGNET Honored to Be Selected for the 2025 VENTURE50 Top 200 List Focusing on Mature Technology Innovation Enterprises。
The preliminary evaluation of VENTURE50 lasted for two months, during which more than a hundred judges from investment institutions assessed companies based on dimensions such as growth speed, technological barriers, commercialization progress, team characteristics, operational capabilities, and industry alignment.2600More than 100 companies were comprehensively evaluated. Ultimately,300All enterprises in the home-based full industry enter the re-evaluation (Top 200 List and New Bud 100 List).
The list was founded by Zero2IPO Group (1945.HK) in 2006 and has been running until now.Is a benchmark for the investment value of high-growth companies in China, after nineteen years of deep cultivation, has witnessed countless enterprises leap from "new shoots" to become "unicorns," and has personally experienced China's industrial upgrading from model innovation to cutting-edge technological breakthroughs over the past 20-plus years.
Signet Therapeutics isPioneer in the Global "Organoid + AI" Empowered Innovative Targeted Drug R&D Model, a national high-tech enterprise and a specialized and innovative enterprise. The company's founding team is composed of outstanding talents from top institutions such as Harvard University, MIT, and the Chinese Academy of Sciences. As the first/corresponding author, they have published more than 20 groundbreaking research achievements in the field of gastric cancer and esophageal cancer in journals with an impact factor of over 20, such as Nature, Nature Medicine, and Cancer Cell, making them a global leader in the research of gastric cancer and esophageal cancer. Since its establishment in Shenzhen at the end of 2020, the company has completed nearly 220 million yuan in financing and project funding, and holds more than 40 core intellectual properties.
The company currently has four first-in-class drug pipelines and one organoid platform. Its core pipeline, SIGX1094R, is the world's first targeted drug for diffuse gastric cancer. It has successively obtained IND approvals from the U.S. FDA and China NMPA, and received Orphan Drug Designation (ODD) and Fast Track Designation (FTD) from the U.S. FDA. The drug won in August 2025."The Galien Award, known as the 'Nobel Prize of the pharmaceutical industry'"Nominated, currently conducting Phase I clinical trials at the Peking University Cancer Hospital. This pipeline is also the world's first drug pipeline advanced to the clinical stage through the "Organoid+AI" technology platform.
Since its establishment at the end of 2020, the company's forward-looking strategic layout of the "Organoid+AI" empowered technology system for innovative targeted cancer drug research and development has gained international authoritative recognition and was featured by a globally renowned biotech media.Fierce Biotech reported on its homepage and commented: "NEXT Generation Paradigm for Cancer Drug DevelopmentIn April 2025, the U.S. FDA officially issued a statement clearly supporting the gradual replacement of traditional animal experiments with organoid and AI technologies, fully verifying the foresight and scientific nature of the company's technical layout from four years ago.
1
END
1
